End-Stage Kidney Disease Clinical Trial
Official title:
Effects of Dialysis-specific Therapeutic Diet in Dialysis Patients
In patients with kidney failure, disturbances in bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, nutrition, and gut microbial metabolites are frequent. Unhealthy diet causes altered mineral metabolism, elevated uremic toxin level, immune dysregulation, inflammation, protein-energy wasting and dysbiosis. The investigators hypothesize that therapeutic diet intervention reverses these uremic complications and thereby reduces cardiovascular risk in patients with kidney failure. In this study, the investigators crafted 4-week dialysis-specific therapeutic diet to illustrate the clinical implications of therapeutic diet for dialysis patients.
In patients with kidney failure, disturbance in bone turnover and mineral metabolism, and nutritional deficiency is prevalent, leading to vascular calcification, uremia, inflammation, immune dysregulation, and gut microbial dysbiosis, and these abnormalities are associated with increased risk of fracture, extraskeletal or vascular calcification and cardiovascular mortality. It is well known that an unhealthy diet plays an important role in bone-mineral metabolism, uremia, inflammation, protein-energy wasting, and dysbiosis, and therefore nutritional therapy may help to manage these uremic complications to reduce cardiovascular risk in patients with kidney failure. Importantly, serum biomarkers regarding the above-mentioned abnormalities are acutely and closely related to food intake. To our knowledge, no study to date has examined the multifactorial effects of nutritional intervention on bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, nutrition, and gut microbial metabolites in dialysis patients. To examine the beneficial effects of nutritional intervention on clinical outcomes, the investigators crafted the dialysis-specific therapeutic diet which was characterized by adequate calorie and protein amounts, natural food ingredients with a low phosphorus-to-protein ratio, higher portions of plant-based food, and high fiber content. In the previous studies, the investigators found that the therapeutic diet rapidly reversed mineral abnormalities within the 1-week intervention period. Among these changes, reduction in serum phosphate level achieved in 2 days, modifications of intact parathyroid hormone (PTH) and calcium levels in 5 days, and reductions in intact and C-terminal fibroblast growth factor-23 (FGF23) levels in 7 days of therapeutic diet intervention. Although the therapeutic diet tended to change uremic toxin level, neither inflammatory nor nutritional markers changed which may be explained by short duration of intervention. It is of interest to know whether the therapeutic diet has a favorable effect on bone turnover, vascular calcification, and gut microbial dysbiosis. In this continuity planning, the investigators are therefore going to analyze the 4-week diet-induced changes in biomarkers regarding bone turnover, vascular calcification, and gut microbial metabolites in addition to the previously assessed mineral metabolism, uremia, inflammation, immunity, and nutrition in dialysis patients. This project aims to explore the multiple diverse effects of dialysis-specific healthy diet on the changes of bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, nutrition, and gut microbial metabolites in dialysis patients. In contrast to the previous approaches, bone biomarkers for both of bone formation and bone resorption, vascular calcification biomarkers, and gut microbial metabolites will be comprehensively examined. Revealing a complex correlation between the nutritional factors and bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, nutrition, and gut microbial dysbiosis, this project may shed light on understanding of diet-mediated bone-mineral and uremic homeostasis and uncover strategies of nutritional therapy. A better knowledge of diet-induced pathway on human body homeostasis may lead to new strategies for preventing fracture, vascular calcification or cardiovascular disease risk. It is to conduct a randomized controlled trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. Subjects with aged older than 20 years, end-stage kidney disease (ESKD) undergoing maintenance dialysis for more than three months, having adequate dialysis and good dietary compliance will be included. Participants will be randomly assigned into two groups: group A and group B. Those in group A will receive study diet for 4 weeks, followed by 16-week washout period and then receive 4-week usual diet. The opposite order of diets will be prescribed in group B. The study meals are prepared in the hospital cafeteria. Dietary compositions of the study diets were analyzed before the start of the study. The study outcome measures are difference in change-from-baseline values of abnormal mineral metabolism, altered bone turnover, vascular calcification, uremic toxin production, immune dysregulation, nutrition, inflammation and gut microbial metabolites between the therapeutic diet and the usual diet. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Completed |
NCT03582592 -
Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis
|
N/A | |
Completed |
NCT02694068 -
Biological Determinants of Peritoneal Dialysis
|
||
Not yet recruiting |
NCT02832505 -
Applications of MRI in Kidney Disease
|
||
Not yet recruiting |
NCT02590081 -
Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT01859884 -
Optimizing Kidney Transplant Informed Consent
|
N/A | |
Completed |
NCT00509236 -
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
|
Phase 3 | |
Completed |
NCT02009514 -
Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients
|
Phase 4 | |
Completed |
NCT01528800 -
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients
|
Phase 2 | |
Completed |
NCT01863914 -
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
|
Phase 2 | |
Withdrawn |
NCT06030050 -
Animal Assisted Intervention for Hemodialysis Outpatients
|
N/A | |
Completed |
NCT04610593 -
Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis
|
N/A | |
Recruiting |
NCT05931276 -
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
|
Phase 3 | |
Completed |
NCT00143741 -
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
|
Phase 1 | |
Active, not recruiting |
NCT02755610 -
Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
|
N/A | |
Recruiting |
NCT03142529 -
Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02342119 -
Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation
|
N/A | |
Recruiting |
NCT05614115 -
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
|
Phase 1 | |
Recruiting |
NCT01111422 -
Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients
|
Phase 4 |